AF1q as a promising new biomarker for neuroblastoma
St. Baldrick’s Foundation posted on LinkedIn about recent paper by Julie D. Saba et al., titled “AF1q is a universal marker of neuroblastoma that sustainsN-Myc expression and drives tumorigenesis” published on Oncogene.
Authors: Babak Oskouian, Joanna Y. Lee, Shahab Asgharzadeh, Ranjha Khan, Meng Zhang, Julia R. Weisbrod, Youn-Jeong Choi, Latika Puri, Ana E. Aguilar, Piming Zhao, Julie D. Saba
“Great news in the fight against pediatric cancer!
Researchers have identified AF1q as a promising new biomarker for neuroblastoma, a type of cancer that originates in early nerve tissues, often around the adrenal glands. Using databases supported by St. Baldrick’s, the study reveals that neuroblastoma cells depend heavily on AF1q for their growth. Notably, turning off AF1q in experimental models led to cell death, suggesting potential new treatment avenues. Future research will explore how AF1q interacts with other cellular proteins to enhance targeted therapies for this cancer.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023